Molindone

Antipsychotic medication
  • C
Routes of
administrationBy mouth (tablets)Drug classTypical antipsychoticATC code
  • N05AE02 (WHO)
Legal statusLegal status
  • US: ℞-only
Pharmacokinetic dataMetabolismHepaticElimination half-life1.5 hoursExcretionMinor, renal and fecalIdentifiers
  • 3-Ethyl-2-methyl-5-(morpholin-4-ylmethyl)-
    1,5,6,7-tetrahydro-4H-indol-4-one
CAS Number
  • 7416-34-4 checkY
PubChem CID
  • 23897
IUPHAR/BPS
  • 207
DrugBank
  • DB01618 ☒N
ChemSpider
  • 22342 checkY
UNII
  • RT3Y3QMF8N
KEGG
  • D08226 checkY
ChEMBL
  • ChEMBL460 checkY
CompTox Dashboard (EPA)
  • DTXSID9023332 Edit this at Wikidata
ECHA InfoCard100.254.109 Edit this at WikidataChemical and physical dataFormulaC16H24N2O2Molar mass276.380 g·mol−13D model (JSmol)
  • Interactive image
  • O=C2c1c(c([nH]c1CCC2CN3CCOCC3)C)CC
  • InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3 checkY
  • Key:KLPWJLBORRMFGK-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Molindone, sold under the brand name Moban, is an antipsychotic which is used in the United States in the treatment of schizophrenia.[1][2] It works by blocking the effects of dopamine in the brain, leading to diminished symptoms of psychosis. It is rapidly absorbed when taken orally.

It is sometimes described as a typical antipsychotic,[3] and sometimes described as an atypical antipsychotic.[4]

Molindone was discontinued by its original supplier, Endo Pharmaceuticals, on January 13, 2010.[5]

Availability and marketing in the USA

After having been produced and subsequently discontinued by Core Pharma in 2015–2017, molindone is available again from Epic Pharma effective December, 2018.[6]

Adverse effects

The side effect profile of molindone is similar to that of other typical antipsychotics. Unlike most antipsychotics, however, molindone use is associated with weight loss.[4][7]

Chemistry

Synthesis

Patent:[8][9] Newer patent:[10]

Condensation of oximinoketone 2 (from nitrosation of 3-pentanone), with cyclohexane-1,3-dione (1) in the presence of zinc and acetic acid leads directly to the partly reduced indole derivative 6. The transformation may be rationalized by assuming as the first step, reduction of 2 to the corresponding α-aminoketone. Conjugate addition of the amine to 1 followed by elimination of hydroxide (as water) would give ene-aminoketone 3. This enamine may be assumed to be in tautomeric equilibrium with imine 4. Aldol condensation of the side chain carbonyl group with the doubly activated ring methylene group would then result in cyclization to pyrrole 5; simple tautomeric transformation would then give the observed product. Mannich reaction of 6 with formaldehyde and morpholine gives the tranquilizer molindone (7).

See also

References

  1. ^ "molindone". F.A. Davis Company.
  2. ^ "Molindone".
  3. ^ Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). "Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients". Am J Geriatr Pharmacother. 6 (4): 198–204. doi:10.1016/j.amjopharm.2008.10.003. PMID 19028375.
  4. ^ a b Bagnall A, Fenton M, Kleijnen J, Lewis R (2007). Bagnall AM (ed.). "Molindone for schizophrenia and severe mental illness". Cochrane Database Syst Rev (1): CD002083. doi:10.1002/14651858.CD002083.pub2. PMID 17253473.
  5. ^ "Drugs to be Discontinued". www.fda.gov. Archived from the original on 2009-06-03.
  6. ^ "NEWS". www.epic-pharma.com. Retrieved 2018-12-12.
  7. ^ Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (November 1999). "Antipsychotic-induced weight gain: a comprehensive research synthesis". The American Journal of Psychiatry. 156 (11): 1686–1696. doi:10.1176/ajp.156.11.1686. PMID 10553730. S2CID 38635470.
  8. ^ SCHOEN KARL, J PACHTER IRWIN; BE 670798  (1965 to Endo Lab).
  9. ^ Irwin J Pachter, Karl Schoen, U.S. patent 3,491,093 (1970 to Endo Lab).
  10. ^ Martin Hanbauer, et al. WO2014042688 (Supernus Pharmaceuticals Inc).
  • v
  • t
  • e
Typical
DisputedAtypicalOthers
  • v
  • t
  • e
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Serotonergics
  • Monoamine reuptake inhibitors
  • Monoamine releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins